Research Progress of Urine Biomarkers in the Diagnosis, Treatment, and Prognosis of Bladder Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jin, Feng | - |
dc.contributor.author | Shahid, Mumammad | - |
dc.contributor.author | Kim, Jayoung | - |
dc.date.accessioned | 2022-02-21T00:40:26Z | - |
dc.date.available | 2022-02-21T00:40:26Z | - |
dc.date.created | 2021-05-20 | - |
dc.date.issued | 2021-05 | - |
dc.identifier.issn | 0065-2598 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/83523 | - |
dc.description.abstract | Bladder cancer (BC) is one of the most common tumor with high incidence. Relative to other cancers, BC has a high rate of recurrence, which results in increased mortality. As a result, early diagnosis and life-long monitoring are clinically significant for improving the long-term survival rate of BC patients. At present, the main methods of BC detection are cystoscopy and biopsy; however, these procedures can be invasive and expensive. This can lead to patient refusal and reluctance for monitoring. There are several BC biomarkers that have been approved by the FDA, but their sensitivity, specificity, and diagnostic accuracy are not ideal. More research is needed to identify suitable biomarkers that can be used for early detection, evaluation, and observation. There has been heavy research in the proteomics and genomics of BC and many potential biomarkers have been found. Although the advent of metabonomics came late, with the recent development of advanced analytical technology and bioinformatics, metabonomics has become a widely used diagnostic tool in clinical and biomedical research. It should be emphasized that despite progress in new biomarkers for BC diagnosis, there remains challenges and limitations in metabonomics research that affects its translation into clinical practice. In this chapter, the latest literature on BC biomarkers was reviewed. © 2021, Springer Nature Switzerland AG. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Springer | - |
dc.relation.isPartOf | Advances in Experimental Medicine and Biology | - |
dc.title | Research Progress of Urine Biomarkers in the Diagnosis, Treatment, and Prognosis of Bladder Cancer | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.doi | 10.1007/978-3-030-63908-2_5 | - |
dc.identifier.bibliographicCitation | Advances in Experimental Medicine and Biology, v.1306, pp.61 - 80 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85105431400 | - |
dc.citation.endPage | 80 | - |
dc.citation.startPage | 61 | - |
dc.citation.title | Advances in Experimental Medicine and Biology | - |
dc.citation.volume | 1306 | - |
dc.contributor.affiliatedAuthor | Kim, Jayoung | - |
dc.type.docType | Book Chapter | - |
dc.subject.keywordAuthor | Biomarkers | - |
dc.subject.keywordAuthor | Bladder Cancer | - |
dc.subject.keywordAuthor | Metabolomics | - |
dc.subject.keywordAuthor | Urine | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.